



Synthesis of some Pyrrolo[2,3-*d*]pyrimidine and 1,2,3-Triazole Isonucleosides

Ratnakar R. Talekar and Richard H. Wightman*


Department of Chemistry, Heriot-Watt University, Riccarton, Edinburgh EH14 4AS, U.K.

Abstract: Nucleoside analogues **8**, **9**, **10** and **11**, in which a pyrrolo[2,3-*d*]pyrimidine ring is linked to a 2-hydroxymethyl-3-hydroxytetrahydrofuran, have been prepared. The azide **16** used as an intermediate in the routes to these compounds also gave access to the 1,2,3-triazole isonucleosides **12** and **13**.


© 1997 Elsevier Science Ltd. All rights reserved.

INTRODUCTION

It has been recognised for some time that 2',3'-dideoxynucleosides can be effective inhibitors of the reverse transcriptase of HIV-1, and indeed dideoxyinosine (ddI, didanosine, **1**)¹ and dideoxycytosine (ddC, zalcitabine, **2**)² are in clinical use against HIV infections. It has also become apparent in recent years that, in addition to the deletion of the 3'-hydroxy function of deoxynucleosides, as in the 2', 3'-dideoxynucleosides, or its replacement by another functional group, as in AZT,³ good antiviral activity can be shown by compounds with a more extensive modification of the deoxyribose unit. Notable compounds of this type with potent anti-HIV activity include those in which the tetrahydrofuran ring is replaced by a 1,3-dioxolane⁴ or a 1,3-oxathiolane ring, as in the very promising 3-thiacytidine (lamivudine, **3**), where the stereoisomer shown displayed the best anti-viral activity.⁵




Also of interest in this area, showing significant and selective anti-HIV activity, are the 'iso-dideoxynucleosides' such as iso-dideoxyadenosine (iso-ddA, **4**) and iso-ddG (**5**), investigated by workers in both Hoffman-La Roche⁶ and Glaxo laboratories.⁷ Recently, Nair and colleagues have prepared iso-dideoxynucleosides in the enantiomeric series, and *S,S*-iso-ddA (**6**), enantiomeric with **4**, proved the most interesting compound of those reported with regard to anti-HIV activity.⁸ Other workers have also reported similar compounds with an additional substituent on the isosugar ring, such as **7**, and again anti-HIV activity was found in some cases.⁹



2',3'-Dideoxynucleosides such as 1 and 2 have the disadvantage as medicinal agents of undergoing rapid hydrolysis of the glycosidic bond under acidic conditions similar to those in the gastric environment.¹⁰ Iso-dideoxynucleosides such as 4 and 5 are, as would be expected, of much greater stability towards acids, with neither of these compounds undergoing detectable decomposition over 24 hours at pH 3 and 37 °C, whereas 2',3'-dideoxyadenosine (ddA) and 2',3'-dideoxyguanosine (ddG) had half-lives of <1 h and ~2 h respectively under these conditions.⁶ There is, therefore, encouragement to synthesise a range of compounds related to iso-ddA (4) including examples with other biologically-significant bases.

In this work we describe the synthesis of compounds 8 - 11 related to iso-ddA but in which the adenine moiety is replaced by a pyrrolo[2,3-*d*]pyrimidine ring. Incorporation of the pyrrolo[2,3-*d*]pyrimidine (7-deazapurine) system into bioactive nucleoside analogues is well documented;¹¹ it is particularly noteworthy that the 7-deaza-analogues of ddA, of ddG, and of their 2',3'-didehydroderivatives, are all, as their 5'-triphosphates, powerful inhibitors of HIV reverse transcriptase.^{11e} The 8-aza-analogue of iso-ddA is also, as its 5'-triphosphate, an active inhibitor of HIV-1 recombinant reverse transcriptase.¹²




The presence of an extra hydroxy function in the isosugar ring of these compounds gives scope for the synthesis of other analogues with various other functionalities, as well as the iso-dideoxynucleosides themselves by removal of the hydroxy group. Its presence also gives the opportunity for incorporation of iso-nucleosides (with either the normal nucleobases or modified ones) into oligonucleotide analogues, in which the iso-nucleosides could be linked either by phosphodiester links, or by one of the many phosphorus-free linkages that have been investigated in recent years in connection with antisense research.¹³

The use of azido-intermediates in the routes to 8 - 11 also permitted the synthesis of the 1,2,3-triazole isonucleosides 12 and 13.

RESULTS AND DISCUSSION

The route used for synthesis of the pyrrolopyrimidine isonucleosides 8, 9 and 10 is indicated in Scheme 1, and is similar to an approach previously reported very briefly for gaining access to such analogues.¹⁴ 1,2-*O*-isopropylidene-α-D-xylofuranose¹⁵ was converted conventionally into its dimesylate 14, and this, on heating

under reflux in methanol containing 1% (v/v) of trifluoroacetic acid, followed by treatment with anhydrous K_2CO_3 , gave the acetal-epoxide **15** in high yield. The tetrahydrofuran **A** is assumed to be formed as an intermediate after the acid treatment, by analogy with other similar cyclizations.¹⁶ The epoxide **15** could be converted cleanly into one regioisomeric azidoalcohol **16** on treatment with NaN_3 and NH_4Cl in aqueous ethanol as reflux,¹⁴ and catalytic hydrogenation then gave the aminoalcohol **17**.




Scheme 1. i, MeOH, TFA, reflux; ii, K_2CO_3 , r.t. (86% overall); iii, NaN_3 , NH_4Cl , $H_2O/EtOH$ (94%); iv, H_2 , PtO_2 , $EtOH$ (90%); v, Et_3N , $EtOCH_2CH_2OH$, reflux (72%); vi, THF, HCl aq., r.t. (81%); vii, TFA, THF/ H_2O , 80 °C, then $NaBH_4$ (70%); viii, NH_3 , MeOH, 100 °C (68%); ix, NaOH, dioxan/ H_2O , reflux (63%); x, thiourea, *n*-propanol, reflux (67%).

The pyrrolopyrimidine ring could then be constructed by reaction of amine **17** with the dichloropyrimidine **18** (prepared from the known aldehyde¹⁷ by treatment with NH_4Cl in ethanol at reflux) in the presence of Et_3N to give the substitution product **19**, which, on stirring in THF and aqueous HCl at room temperature underwent smooth cyclization to the pyrrolopyrimidine **20**. The second acetal grouping in **19** was stable to these mild acidic conditions, presumably due to the electron-withdrawing effect of the oxygen of the tetrahydrofuran ring. The structure of **20** was assured by NMR studies, including COSY experiments to define the connectivities, and these experiments served to confirm the regiochemistry in the nucleophilic opening of the epoxide **15**.


Hydrolysis of **20** under more vigorous acidic conditions, followed by treatment with NaBH_4 , gave the diol **21** as a crystalline solid, which could be converted into the adenosine analogue **8** by treatment with methanolic ammonia at 100°C . The chlorocompound **21** could also act as a precursor for the inosine analogue **9**, into which it was converted by alkaline hydrolysis, and for the thione **10**, which was obtained (67%) when **21** was heated under reflux with thiourea in *n*-propanol.

Our initial approach to the guanosine analogue **11** proceeded along similar lines (Scheme 2). Thus the amine **17**, on reaction with the dichloropyrimidine **22**^{11c} gave the bis-acetal **23** which again underwent clean cyclization to the pyrrolopyrimidine **24** (76%) on treatment with THF and dilute aqueous HCl at room temperature. Substitution of the chloro-function to give **25** proceeded smoothly, but attempts at hydrolysis of **25** under various acidic conditions, and subsequent reduction, either using borohydride or by catalytic hydrogenation,¹⁸ proved unrewarding. Similarly, attempts at the selective hydrolysis of the acetal of **24** and subsequent reduction did not prove successful.




Scheme 2. i, Et_3N , $\text{EtOCH}_2\text{CH}_2\text{OH}$, reflux (62%); ii, THF, HCl aq., r.t. (76%); iii, NaOH , dioxan/ H_2O , reflux (72%).

Thus we chose to introduce the primary alcohol at an earlier stage (Scheme 3). Acidic hydrolysis of **16**, followed by treatment with controlled amounts of NaBH_4 gave the azidodiols **26** in moderate yield, and this was reduced catalytically to aminodiols **27** in high yield. Condensation of **27** with dichloropyrimidine aldehyde **28**^{11c} (Et_3N , ethoxyethanol, reflux) gave the pyrrolopyrimidine **29**, and this on acidic hydrolysis gave the desired guanosine analogue **11**.



Scheme 3. i, dioxan, HCl aq., reflux, then NaBH₄ (46%); ii, H₂, PtO₂, EtOH (90%); iii, Et₃N, EtOCH₂CH₂OH, reflux (38.5%); iv, HCl aq (1M), reflux (58%).

The use of azide intermediates in the routes to the pyrrolopyrimidines suggested that they could also provide access to 1,2,3-triazole nucleoside analogues. Cyclization of **16** with DMAD gave (Scheme 4) the adduct **30** in high yield, and this could be cleanly converted to the diamide **31** with methanolic ammonia. Acidic hydrolysis, followed by treatment with NaBH₄ then gave the triazole isonucleoside **12**.



Scheme 4. i, DMAD, DME, reflux (96%); ii, NH₃, MeOH, r.t. (92%); iii, dioxan/TFA/H₂O, r.t., then NaBH₄, MeOH (45%); iv, methyl propiolate, DME, reflux (96%); v, NH₃, MeOH, r.t. (90%); vi, as iii (61%).

When **16** was heated under reflux in DME with methyl propiolate, two cycloadducts **32** (14%) and **33** (79%) were obtained. The regiochemical assignments were supported by the observation that, in the ¹H-NMR

spectrum of the minor isomer **32**, the signals for both 3'-H and 4'-H appeared at lower field (δ 4.87 and 5.59 respectively) than did the equivalent signals for the major product **33** (δ 4.58 and 5.15), as would be expected from the deshielding effect of the carbonyl group. Ammonolysis of **33** gave the crystalline amide **34**, convertible in the usual manner into the isonucleoside **13**, which can be regarded as an analogue of the well-established antiviral nucleoside ribavirin (1- β -D-ribofuranosyl-1,2,4-triazole-3-carboxamide, virazole).¹⁹

Antiviral Testing - Compounds **8** - **13**, **21**, **24**, **31** and **34** were tested against HIV-1_{MN} in C8166 cells, but in all cases concentrations >200 μ M were necessary to reduce Ag gp120 by 50% in infected cells. However in the light of previous findings,^{11e,12} it remains of interest to evaluate these compounds as their triphosphates at the primary alcohol group against HIV-1 reverse transcriptase.

EXPERIMENTAL

NMR spectra were recorded on a Bruker WP 200 SY spectrometer. ¹H-Spectra were obtained at 200 MHz, and ¹³C-spectra at 50 MHz, in CDCl₃ as solvent unless otherwise stated. Coupling constants are measured in Hz. Mass spectrometry was performed using V.G. updated MS 9 and V.G. ZABE high resolution EI/FAB instruments. Specific rotations were measured at room temperature using a Bendix-NPL 143D automatic polarimeter (path length 1 cm); units for [α]_D values are 10⁻¹ deg cm² g⁻¹. Melting points were determined using an Electrothermal MK II melting point apparatus and are uncorrected. Column chromatography was carried out using Kieselgel H type 60 (Merck), an external pressure being applied to the top of columns. Organic extracts were dried over anhydrous sodium sulphate. Light petroleum refers to material of boiling range 40-60 °C.

1,2-O-Isopropylidene-3,5-di-O-methanesulfonyl- α -D-xylofuranose (14). - To a solution of 1,2-O-isopropylidene- α -D-xylofuranose¹⁵ (15.8 g, 83 mmol) and triethylamine (18.5 g, 183 mmol) in dry dichloromethane (200 ml) at 0°C was added dropwise with stirring methanesulfonyl chloride (21.0 g, 183 mmol). The mixture was allowed to warm to r.t., stirred for 1 hour, washed with saturated NaHCO₃ aq. (2 x 100ml) and brine (100 ml), dried and evaporated. The residue was chromatographed on silica gel, with dichloromethane-methanol (98:2) as eluant to give the dimesylate **14** (21.8 g, 76%) as an oil; δ _H 1.31 and 1.50 (each 3H, s, CMe₂), 3.08 and 3.12 (each 3H, s, SO₂Me), 4.40 (2H, d, *J* 6.6, 5-H₂), 4.56 (1H, dt, *J* 6.6, 6.6 and 3.2, 4-H), 4.82 (1H, d, *J* 3.7, 2-H), 5.07 (1H, d, *J* 3.2, 3-H), 5.97 (1H, d, *J* 3.7, 1-H) (Found: C, 35.0; H, 5.5; S, 18.1. C₂₀H₁₈O₉S₂ requires C, 34.68; H, 5.20, S, 18.49%).

(2R, 3R, 4R)-2-(Dimethoxymethyl)-3,4-epoxytetrahydrofuran (15) - A solution of the dimesylate **14** (21.3 g, 61.5 mmol) in dry methanol (400 ml) containing TFA (4 ml) was heated under reflux for 40 h. The mixture was cooled to r.t. and stirred with anhydrous K₂CO₃ (24.2 g, 0.175 mol) overnight. The mixture was filtered and the solids washed with dichloromethane (2 x 50 ml). The combined filtrates were evaporated and the residue was chromatographed on silica gel, with ethyl acetate - light petroleum (1:1) as eluent to give the epoxide **15** (8.46 g, 86%) as an oil, [α]_D +19.5 (*c* 1.02, CHCl₃); δ _H 3.43 and 3.45 (each 3H, s, O Me), 3.75-3.85 (3H, m, 3-H, 4-H, 5 β -H), 3.96 (1H, br d, *J* 10.1, 5 α -H), 4.07 (1H, br.d, *J* 4.6, 2-H), 4.27 [1H, d, *J* 4.4, CH(O Me)₂]; *m/z* (FAB) 161 (MH⁺), 129 (M-OMe)⁺ (Found: C, 52.2; H, 7.8. C₇H₁₂O₄ requires C, 52.50; H, 7.50%).

(2R, 3R, 4S)-4-Azido-2-dimethoxymethyl-3-hydroxytetrahydrofuran (16) - A solution of epoxide **15** (6.0 g, 37.5 mmol), sodium azide (4.88 g, 75 mmol) and ammonium chloride (4.97 g, 94 mmol) in water (40 ml) and ethanol (140 ml) was heated under reflux for 24 h. The residue after evaporation was extracted with dichloromethane (2 x 100 ml). After evaporation, the residue was chromatographed on silica, with ethyl acetate-light petroleum (2:3) as eluent to give the azidoalcohol **16** (7.13 g, 94%) as an oil, [α]_D +38.7 (*c* 3.15, CHCl₃); ν _{max} (film) 3425 (br) and 2104 cm⁻¹; δ _H 2.3 (1H, br.s, OH), 3.43 and 3.47 (each 3H, s, OMe), 3.76

(1H, dd, *J* 6.3 and 5.4, 2-H), 3.85 (1H, dd, *J* 8.9 and 3.6, 5'-H), 4.0 (1H, m, 4-H), 4.05 (1H, dd, *J* 8.8 and 5.8, 5'-H), 4.20 (1H, dd, *J* 5.2 and 3.5, 3-H), 4.38 [(1H, d, *J* 6.3, CH(OMe)₂]; δ_c 54.2, 55.9, 66.8 and 70.4 (OMe), 77.6, 84.2 and 104.7 [CH(OMe)₂] (Found: C, 41.4; H, 6.6. C₇H₁₃N₃O₄ requires C, 41.37; H, 6.40%).

(2R, 3R, 4S)-4-Amino-2-dimethoxymethyl-3-hydroxytetrahydrofuran (17) - A solution of azide 16 (7.0 g, 34.5 mmol) in ethanol (100 ml) was stirred with PtO₂ (100 mg) under hydrogen overnight. After filtration through celite and evaporation, the residue was chromatographed on silica gel, with dichloromethane-methanol (20:1) as eluent, to give the amine 17 (5.48 g, 90%) as an oil, [α]_D +24.3 (*c* 1.28, CHCl₃); δ_H 3.40-3.45 (1H, m, 4-H), 3.45 and 3.50 (each 3H, s, OMe), 3.6-3.8 (2H, m), 3.95 - 4.1 (2H, m), 4.42 [1H, d, *J* 6.0, CH(OMe)₂]; *m/z* 177 (M⁺), 146 (M-OMe)⁺, 102 [M-CH(OMe)₂]⁺ (Found: C, 45.7; H, 9.0; N, 7.5. C₇H₁₅NO₄ requires C, 45.40; H, 8.64; N, 7.56%).

4,6-Dichloro-5-(2,2-diethoxyethyl)pyrimidine (18). - To a solution of sodium periodate (25.9 g, 121 mmol) and osmium tetroxide (75 mg) in water (130 ml) was added 5-allyl-4,6-dichloropyrimidine¹⁷ (9.18 g, 48.5 mmol) in methanol (130 ml). The mixture was stirred at 0 °C for 5 h and then overnight at r.t. Aqueous sodium sulfite (5%, 100 ml) was added, the solids were filtered, and the solution was lyophilised. The residue was partitioned between dichloromethane (200 ml) and water (2 x 50 ml). Evaporation of the dried organic phase gave the crude aldehyde (8.1 g) as an oil. This material and ammonium chloride (0.224 g, 4.2 mmol) were heated under reflux in dry ethanol for 3 h. The residue after evaporation was chromatographed on silica, with ethyl acetate-petrol (5:95) as eluent, to give the acetal 18 (9.8 g, 88%) as an oil; δ_H 1.11 (6H, t, *J* 7.5, OCH₂CH₃), 3.25 (2H, d, *J* 6.0, ArCH₂), 3.35-3.5 and 3.6-3.8 (each 2H, m, OCH₂CH₃), 4.78 [1H, t, *J* 6.0, CH(OEt)₂], 8.61 (1H, s, Ar-H).

(2'R, 3'R, 4'S)-4-Chloro-5-(2,2-diethoxyethyl)-6-(2'-dimethoxymethyl-3'-hydroxytetrahydrofuran-4'-yl)-amino-pyrimidine (19). - A solution of amine 17 (1.77 g, 10 mmol), dichloropyrimidine 18 (2.65 g, 10 mmol) and triethylamine (20 ml) in 2-ethoxyethanol (40 ml) was heated under reflux for 7 h. The residue after evaporation was partitioned between dichloromethane (100 ml) and water (2 x 20 ml). The organic layer was dried and evaporated, and the residue was chromatographed on silica, with dichloromethane-methanol (20:1) as eluent, to give the aminopyrimidine 19 (2.91 g, 72%) as an oil; δ_H 1.25 (6H, q, *J* 7, OCH₂Me), 2.92 (2H, d, *J* 5.5, CH₂ benzylic), 3.44 and 3.46 (each 3H, s, OMe), 3.40 - 3.65 (2H, m), 3.7 - 3.8 (3H, m), 3.95 (1H, t, *J* 5.5), 4.12 (1H, dd, *J* 5.5 and 4.5), 4.2 - 4.4 (2H, m), 4.41 [1H, d, *J* 4.9, CH(OMe)₂], 4.60 [1H, t, *J* 5.5, CH(OEt)₂], 6.65 (1H, br d, NH), 8.30 (1H, s, 2-H) (Found: C, 50.4; H, 7.1; N, 10.3. C₁₇H₂₈ClN₃O₆ requires C, 50.37; H, 6.91; N, 10.37%).

(2'R,3'R,4'S)-4-Chloro-7-(2'-dimethoxymethyl-3'-hydroxy-tetrahydrofuran-4'-yl)pyrrolo[2,3-d]pyrimidine (20) - A solution of the bis-acetal 19 (0.542 g, 1.33 mmol) in THF (10 ml) and aqueous HCl (1.5M, 2.5 ml) was stirred at r.t. for 72 h. The mixture was neutralised with NaOH aq. and lyophilized. The residue was chromatographed on silica gel, with dichloromethane-methanol (99:1) as eluent, to give the pyrrolopyrimidine 20 (0.34 g, 81%) as an amorphous solid, [α]_D -25.3 (*c* 1.18, CHCl₃); δ_H 2.6 (1H, br s, OH), 3.45 (6H, s, OMe), 4.01 (1H, t, *J* ~6, 2'-H), 4.27 (1H, dd, *J* 9.9 and 5.2, 5'-H), 4.45 (1H, dd, *J* 9.8, 6.7, 5'-H), 4.46 [1H, d, *J* 5.0, CH(OMe)₂], 4.55 (1H, dd, *J* 5.5 and 4.5, 3'-H), 5.17 (1H, ddd, *J* 6.6, 5.0, 4.5, 4'-H) 6.63 (1H, d, *J* 3.5, 5-H), 7.37 (1H, d, *J* 3.5, 6-H), 8.63 (1H, s, 2-H) (Found: C, 49.5; H, 5.0; N, 13.1. C₁₃H₁₆ClN₃O₄ requires C, 49.68; H, 5.09; N, 13.37%).

(2'S, 3'R, 4'S)-4-Chloro-7-(3'-hydroxy-2'-hydroxymethyl-tetrahydrofuran-4'-yl)pyrrolo[2,3-d]pyrimidine (21). - A solution of the dimethyl acetal 20 (208 mg, 0.66 mmol) in THF (1.6 ml) and aqueous TFA (1%, 1 ml) was stirred at 80 °C for 5 h. After cooling, the solution was neutralized with NaOH aq. (1M) to pH7, sodium borohydride (25 mg, 0.66 mmol) was added, and the mixture stirred for 1 h. After quenching with acetic acid, evaporation gave a residue that was chromatographed on silica gel, with dichloromethane-methanol (95:5) as eluent, to give the diol 21 (124 mg, 70%), m.p. 178-180 °C (from methanol), [α]_D +21.1 (*c* 0.9, DMSO); δ_H

(DMSO- d_6) 3.5 - 3.7 (3H, m, 2'-H, CH_2OH), 4.02 (1H, dd, J 9.6 and 5.0, 5'- a -H), 4.18 (1H, dd, J 9.6 and 6.4, 5'- b -H), 4.30 (1H, q, J ~5, 3'-H), 4.95 (1H, t, J 5, CH_2OH), 5.18 (1H, dt, J 6.4, 5.0, 5.0, 4'-H), 5.75 (1H, d, J 6, OH), 6.70 (1H, d, J 4.0, 5-H), 7.85 (1H, d, J 4.0, 6-H), 8.68 (1H, s, 2-H); m/z 269/271 (M^+) (Found: M^+ 271.0512; calc for $C_{11}H_{12}^{37}ClN_3O_3$, 271.0512. Found: C, 48.9; H, 4.7; N, 15.7. $C_{11}H_{12}ClN_3O_3$ requires C, 49.09; H, 4.46; N, 15.61%).

(2'S, 3'R, 4'S)-4-Amino-7-(3'-hydroxy-2'-hydroxymethyl-tetrahydrofuran-4'-yl)pyrrolo [2,3-d]pyrimidine (8) - A solution of the chlorocompound 21 (135 mg, 0.5 mmol) in saturated methanolic ammonia (25 ml) was heated in a pressure reactor at 100 °C for 24 h. The residue after evaporation was chromatographed on silica gel, with dichloromethane-methanol (9:1) as eluent, to give the aminocompound 8 (85 mg, 68%), m.p. 190-192 °C (from methanol), $[\alpha]_D^{+13.9}$ (c 1.01, MeOH); δ_H (DMSO- d_6) 3.45-3.70 (3H, m, 2'-H, CH_2OH), 3.89 (1H, dd, J 9.5 and 5.0, 5'- a -H), 4.12 (1H, dd, J 9.4 and 6.9, 5'- b -H), 4.24 (1H, q, J ~5.5, 3'-H), 4.88 (1H, t, CH_2OH), 5.02 (1H, dt, J 6.7, 5.0, 5.0; 4'-H), 5.65 (1H, d, J 5.5, OH), 6.55 (1H, d, J 3.6, 5-H), 7.0 (2H, br.s, NH_2), 7.22 (1H, d, J 3.6, 6-H), 8.04 (1H, s, 2-H); δ_C (DMSO- d_6) 61.0 (CH_2OH), 61.5 (C-2'), 70.1 (C-3'), 76.2 (C-5'), 85.7 (C-4'), 99.0 (C-5), 102.3 (C-4a), 121.4 (C-6), 151.4 (C-2), 149.6 and 157.4 (C-4 and C-7a); m/z (EI) 250 (M^+), 134 (Base $^+$) [Found: MH^+ (FAB) 251.1144 Calc. for $C_{11}H_{15}N_4O_3$ 251.1144].

(2'S, 3'R, 4'S)-7-(3'-Hydroxy-2'-hydroxymethyl-tetrahydrofuran-4'-yl)pyrrolo[2,3-d]pyrimidine-4(3H)-one (9). - A solution of chlorocompound 21 (94 mg, 0.35 mmol) in dioxan (15 ml) and NaOH aq (1M, 5 ml) was heated under reflux for 42 h. After neutralization with HCl aq (1M) and lyophilization, the residue was chromatographed on silica gel, with dichloromethane-methanol (9:1) as eluent, to give the pyrrolopyrimidinone 9 (56 mg, 63%), m.p. 202-204 °C (from methanol); δ_H (DMSO- d_6) 3.5 - 3.7 (3H, m, 2'-H, CH_2OH), 3.86 (1H, dd, J 9.3 and 5.3, 5'- a -H), 4.12 (1H, dd, J 9.3 and 6.6, 5'- b -H), 4.23 (1H, q, J ~6, 3'-H), 4.80 (1H, t, J ~7, OH), 5.02 (1H, q, J ~6, 4'-H), 5.65 (1H, d, J 6, OH), 6.50 (1H, d, J 4.0, 5-H), 7.23 (1H, d, J 4.0, 6-H), 7.90 (1H, s, 2-H), 11.9 (1H, br s, NH); m/z (EI) 251 (M^+), 135 (Base $^+$) [Found: MH^+ (NH_3 Cl) 252.0984. Calc. for $C_{11}H_{14}N_3O_4$, 252.0984].

(2'S, 3'R, 4'S)-7-(3'-Hydroxy-2'-hydroxymethyl-tetrahydrofuran-4'-yl)pyrrolo[2,3-d]pyrimidin-4(3H)-thione (10). - A solution of chlorocompound 21 (96 mg, 0.36 mmol) and thiourea (28 mg, 0.36 mmol) in *n*-propanol was heated under reflux for 4h. The residue on evaporation was chromatographed on silica gel, with dichloromethane-methanol (20:1) as eluent, to give the thione 10 (64 mg, 67%), m.p. 198-200 °C (from methanol), $[\alpha]_D^{+65.4}$ (c 1.03, MeOH); δ_H (DMSO- d_6 + D_2O) 3.4-3.7 (3H, m, 2'-H, CH_2OH), 3.96 (1H, dd, J 9.0 and 4.7, 5'- a -H), 4.1-4.3 (2H, m, 3'-H, 5'- b -H), 5.02 (1H, m, 4'-H), 6.69 (1H, d, J 3.5, 5-H), 7.39 (1H, d, J 3.5, 6-H), 8.07 (1H, s, 2-H); a spectrum recorded in DMSO- d_6 also showed signals at δ 4.9 (1H, br.s, OH), 5.70 (1H, d, OH) and 13.50 (1H, br.s, NH); δ_C (DMSO- d_6) 60.8 and 62.2 (CH), 70.2 (C-5'), 76.8 (CH), 85.4 (CH), 105.0 (C-5), 120.4 (q), 125.2 (C-6), 143.1 (C-2), 143.4 (q), 175.8 (C=S) [Found: MH^+ (FAB) 268.0768. Calc. for $C_{11}H_{14}N_3O_3S$, 268.0756].

(2'R, 3'R, 4'S)-2-Amino-4-chloro-5-(2,2-diethoxyethyl)-6-(2'-dimethoxymethyl-3'-hydroxy-tetrahydrofuran-4'-yl)-aminopyrimidine (23). - Amine 17 (1.77 g, 10 mmol) and dichloropyrimidine 22 (2.8 g, 10 mmol) were treated and processed as in the preparation of 19 to give the diaminopyrimidine 23 (2.61 g, 62%) as an oil; δ_H 1.20 (6H, q, J 7, OCH_2Me), 3.30 (2H, d, J 5.0, benzylic), 3.44 and 3.46 (each 3H, s, OMe), 3.45 - 3.6 (2H, m) 3.60 - 3.85 (3H, m), 3.93 (1H, t, J 6.0, 2'-H), 4.1 - 4.4 (3H, m), 4.40 [1H, d, J 5, CH (O Me)], 4.48 [1H, t, J 5.0, CH (OEt)], 5.20 (2H, br.s, NH_2), 6.55 (1H, br.d, NH) (Found: C, 48.3; H, 6.6, N, 13.4. $C_{17}H_{29}ClN_4O_6$ requires C, 48.57; H, 6.9; N, 13.33%).

(2'R, 3'R, 4'S)-2-Amino-4-chloro-7-(2'-dimethoxymethyl-3'-hydroxytetrahydrofuran-4'-yl)-pyrrolo[2,3-d]pyrimidine (24). - A solution of the bisacetal 23 (1.51 g, 3.59 mmol) in THF (40 ml) and HCl aq. (1.5M, 10 ml) was stirred at r.t. for 3 days. The mixture was neutralized with IR-45 resin (OH $^-$ form), filtered and evaporated. Chromatography of the residue on silica gel, with dichloromethane-methanol (98:2) as eluent,

gave the pyrrolopyrimidine **24** (0.90 g, 76%) as a syrup, $[\alpha]_D -73.8$ (c 0.975, CHCl_3); δ_H 3.42 and 3.45 (each 3H, s, OMe), 4.01 (1H, t, J 5.5, 2'-H), 4.24 (1H, dd, J 10.0 and 5.0, 5'-H), 4.3-4.4 [2H, m, 5'-H_b, CH (OMe)₂], 4.47 (1H, dd, J 5.5 and 4.7, 3'-H), 4.93 (1H, m, 4'-H), 5.5 (1H, br.s, OH), 6.43 (1H, d, J 3.7, 5-H), 6.98 (1H, d, J 3.7, 6-H); m/z (FAB) 329 (MH⁺), 297 (M-MeO)⁺ (Found: C, 47.3; H, 5.0; N, 16.8. $\text{C}_{13}\text{H}_{17}\text{ClN}_4\text{O}_4$ requires C, 47.56; H, 5.18; N, 17.07%).

(2'R, 3'R, 4'S)-2-Amino-7-(2'-dimethoxymethyl-3'-hydroxytetrahydrofuran-4'-yl)pyrrolo[2,3-d]pyrimidine-4(3H)-one (**25**). - A solution of chlorocompound **24** (463 mg, 1.41 mmol) in dioxan (10 ml) and NaOH aq. (1M, 10 ml) was heated under reflux for 24 h. The mixture was cooled, neutralized to pH 7 with HCl aq. (1M) and evaporated. Chromatography on silica gel, with dichloromethane-methanol (20:1) as eluent, gave the pyrrolopyrimidinone **25** (320 mg, 73%) as an amorphous solid; δ_H (DMSO- d_6) 3.35 (6H, s, OMe), 3.70 (1H, t, J 5.0, 2'-H), 3.86 (1H, dd, J 9.8, 6.0, 5'-H), 4.05 (1H, dd, J 9.8, 7.0, 5'-H), 4.28 (1H, q, J ~ 6, 3'-H), 4.80 (1H, m, 4'-H), 5.15 (1H, d, J 6, OH), 6.2 (2H, br.s, NH₂), 6.26 (1H, d, J 3.5, 5-H), 6.86 (1H, d, J 3.5, 6-H), 10.3 (1H, br.s, NH) [Found: MH⁺ (FAB) 311.1362. Calc for $\text{C}_{13}\text{H}_{19}\text{N}_4\text{O}_5$ 311.1355].

(2S, 3R, 4S)-4-Azido-3-hydroxy-2-(hydroxymethyl)tetrahydrofuran (**26**) - A solution of acetal **16** (2.39 g, 11.8 mmol) in dioxan (24 ml) and HCl aq. (0.3 M, 15 ml) was heated under reflux for 3 h. After cooling, the mixture was adjusted to pH 7 with NaOH aq. (1 M) and treated with sodium borohydride (446 mg, 11.8 mmol) for 1 h. Acetic acid was added to destroy excess borohydride and the mixture was lyophilized. Chromatography on silica, with dichloromethane-methanol (9:1) as eluent gave the azidodiol **26** (0.855 g, 46%) as an oil, $[\alpha]_D +2.2$ (c 1.8, MeOH); δ_H (DMSO- d_6) 3.35-3.60 (3H, m), 3.69 (1H, dd, J 9.6 and 3.0, 5'-H), 3.80-4.0 (3H, m), 4.80 (1H, t, J 5.5, CH_2OH), 5.60 (1H, d, J 4.6, OH); δ_C (DMSO- d_6) 61.3, 67.3, 69.4, 76.1 and 86.0 [Found: MH⁺ (NH₃ Cl) 160.0722. Calc for $\text{C}_5\text{H}_{10}\text{N}_3\text{O}_3$, 160.0722].

(2S, 3R, 4S)-4-Amino-3-hydroxy-2-(hydroxymethyl)tetrahydrofuran (**27**) - Azide **26** (0.80 g, 5.0 mmol) in ethanol (50 ml) was hydrogenated at 1 atm. over PtO₂ (30 mg) for 24h. The mixture was filtered through celite which was washed well with methanol. Evaporation and chromatography of the residue over silica gel, with dichloromethane-methanol (9:1) as eluent, gave the aminodiol **27** (0.605 g, 90%) as an oil; δ_H (DMSO- d_6) 3.10 (1H, m, 4-H), 3.2 (4H, br. s) 3.35-3.55 (3H, m), 3.6-3.7 (2H, m), 3.76 (1H, dd, J 10, 6, 5'-H); δ_C (DMSO- d_6) 61.5 (CH₂), 67.2 (CH), 69.4 (CH₂), 76.5 (CH), 86.4 (CH). [Found: MH⁺ (NH₃ Cl) 134.0810. Calc for $\text{C}_5\text{H}_{12}\text{NO}_3$ 134.0816].

(2'S, 3'R, 4'S)-2-Amino-4-chloro-7-[(3'-hydroxy-2'-hydroxymethyl)-tetrahydrofuran-4'-yl]pyrrolo[2,3-d]pyrimidine (**29**) - A solution of amine **27** (0.543 g, 4.08 mmol), dichloropyrimidine **28** (0.925 g, 4.5 mmol) and triethylamine (10 ml) in 2-ethoxyethanol (20 ml) was heated under reflux for 5h. The residue after evaporation was chromatographed on silica gel, with dichloromethane-methanol (9:1) as eluent, to give the pyrrolopyrimidine **29** (0.445 g, 38.5%), m.p. 146-148 °C (from methanol-ethyl acetate), $[\alpha]_D -47.8$ (c 1.01, MeOH); δ_H 3.4-3.7 (3H, m, 2'-H, CH_2OH), 3.84 (1H, dd, J 9.6 and 4.9, 5'-H), 4.10 (1H, dd, J 9.6 and 6.8, 5'-H), 4.23 (1H, q, J ~5, 3'-H), 4.85-4.95 (2H, m, 4'-H, CH_2OH), 5.55 (1H, d, J 5.6, OH), 6.34 (1H, d, J 3.7, 5-H), 6.70 (2H, br. s, NH₂), 7.27 (1H, d, J 3.7, 6-H); δ_C (DMSO- d_6) 61.2 (CH₂OH), 61.9 (CH), 70.6 (C-5), 76.5 (CH), 86.2 (CH), 99.7 (C-5), 108.9 (q), 124.0 (C-6), 151.6, 154.0 and 159.6 [Found: MH⁺ (FAB) 285.0758. Calc for $\text{C}_{11}\text{H}_{14}\text{ClN}_4\text{O}_3$, 285.0754].

(2'S,3'R,4'S)-2-Amino-7-[(3'-hydroxy-2'-hydroxymethyl)-tetrahydrofuran-4'-yl]pyrrolo[2,3-d]pyrimidin-4(3H)-one (**11**). - A solution of chlorocompound **29** (0.284 g, 1 mmol) in HCl aq. (1M, 20 ml) was heated under reflux for 16 h and then lyophilized. The residue was evaporated with ethanol (2 x 25ml), dissolved in methanol, and adjusted to pH 7 with NaOH aq. (1M). The residue after evaporation was chromatographed on silica gel, with dichloromethane-methanol (9:1) as eluent to give the pyrrolopyrimidinone **11** (153 mg, 58%), m.p. 196-200 °C (dec.) (from methanol), $[\alpha]_D +3.3$ (c 0.92, MeOH); δ_H (DMSO- d_6) 3.45 - 3.65 (3H, m, 2'-H, CH_2OH), 3.81 (1H, dd, J 9.5 and 4.9, 5'-H), 4.05 (1H, dd, J 9.5 and 6.9, 5'-H), 4.19 (1H, dd, $J_{2',3'} 5.5$, $J_{3',4'}$

4.5, 3'-H), 4.83 (1H, dt, J 6.6, ~ 4.7, ~ 4.7, 4'-H), ~6.0 (4H, br.s, NH₂, OH), 6.30 (1H, d, J 3.5, 5-H), 6.85 (1H, d, J 3.5, 6-H), 10.7 (1H, br.s, NH) [Found: MH⁺ (FAB) 267.1095. Calc for C₁₁H₁₅N₄O₄, 267.1093].

(2'R, 3'R, 4'S)-4,5-Bis(methoxycarbonyl)-1-(2'-dimethoxymethyl-3'-hydroxytetrahydrofuran-4'-yl)-1,2,3-triazole (30). - A solution of azide 16 (2.03 g, 10 mmol) and DMAD (1.85 g, 13 mmol) in 1, 2-dimethoxyethane (20 ml) was heated under reflux for 3 h. The residue after evaporation was chromatographed on silica gel, with dichloromethane-methanol (50:1) as eluent, to give the triazole 30 (3.31 g, 96%) as an oil, $[\alpha]_D +7.9$ (c 3.02, CHCl₃); δ_H 3.45 [6H, s, CH(OMe)₂], 3.90 (1H, t, J 5.5, 2'-H), 3.96 and 3.99 (each 3H, s, CO₂Me), 4.37 (1H, dd, J 10.0 and 7.0, 5'-H), 4.41 (1H, dd, J 10.0 and 4.5, 5'-H), 4.53 [1H, d, J 5.5, CH(OMe)₂], 4.82 (1H, dd, J 7.0, 5.5, 3'-H), 5.28 (1H, dt, J 7.0, 7.0, 4.5, 4'-H) (Found: C, 45.5; H, 5.4; N, 11.9. C₁₃H₁₉N₃O₈ requires C, 45.21; H, 5.50; N, 12.17%).

(2'R, 3'R, 4'S)-4,5-Bis(carboxamido)-1-(2'-dimethoxymethyl-3'-hydroxytetrahydrofuran-4'-yl)-1,2,3-triazole (31). A solution of diester 30 (1.67 g, 4.83 mmol) in saturated methanolic ammonia was left to stand at r.t. overnight. The residue after evaporation was crystallized from ethyl acetate to give the diamide 31 (1.42 g, 92%), m.p. 114-116°C, $[\alpha]_D +66.3$ (c 2.0, MeOH); δ_H (DMSO-d₆) 3.32 and 3.35 (each 3H, s, OMe), 3.78 (1H, dd, J 7.0 and 5.0, 2'-H), 3.92 (1H, dd, J 10.0 and 3.5, 5'-H), 4.17 (1H, dd, J 10.0 and 6.0, 5'-H), 4.54 (1H, d, J 7.0, CH(OMe)₂), 4.85 (1H, m, 3'-H), 5.75 (2H, m, 4'-H, OH), 8.15, 8.20, 8.50 and 10.30 (each 1H, NH); δ_C (DMSO-d₆) 53.4 and 54.2 (OMe), 68.6, 71.2, 76.1, 85.1, 103.2 [CH(OMe)₂], 131.4 and 139.1 (C-4, C-5), 158.3 and 163.0 (amide); m/z (FAB) 338 (MNA)⁺, 316 (MH)⁺, 284 (M-MeO)⁺ [Found: (M-MeO)⁺ (EI) 284.09914. Calc for C₁₀H₁₄N₅O₅ 284.09949].

(2'S, 3'R, 4'S)-4,5-Bis(carboxamido)-1-(3'-hydroxy-3'-hydroxymethyltetrahydrofuran-4'-yl)-1,2,3-triazole (12). - A solution of acetal 31 (0.654 g, 2.07 mmole) in dioxan (8 ml) and aqueous TFA (25%, 10 ml) was stirred at r.t. for 48 h. The residue after evaporation, dissolved in methanol (20 ml) and dioxan (20 ml), was treated with sodium borohydride (98 mg, 2.6 mmol) for 1 h. The mixture was quenched with acetic acid and lyophilized. Chromatography on silica gel with dichloromethane-methanol (95:5) as eluant gave the diol 12 (254 mg, 45%) m.p. 210-212°C (from ethyl acetate), $[\alpha]_D +52.7$ (c 1.02, H₂O); δ_H (DMSO-d₆) 3.5-3.8 (3H, m, 2'-H, CH₂OH), 3.92 (1H, dd, J 9.6 and 4.8, 5'-H), 4.22 (1H, dd, J 9.6 and 7.2, 5'-H), 4.73 (1H, q, J ~4, 3'-H), 4.85 (1H, t, J 6, CH₂OH), 5.66 (1H, d, J 6, OH), 5.85 (1H, m, 4'-H), 8.12, 8.20, 8.50 and 10.2 (each 1H, br.s, NH₂) [Found: MH⁺ (NH₃ Cl) 272.0995. Calc for C₉H₁₄N₅O₅ 272.0995].

(2'R, 3'R, 4'S)-1-(2'-Dimethoxymethyl-3'-hydroxytetrahydrofuran-4'-yl)-5-methoxycarbonyl-1,2,3-triazole (32) and (2'R, 3'R, 4'S)-1-(2'-Dimethoxymethyl-3'-hydroxytetrahydrofuran-4'-yl)-4-methoxycarbonyl-1,2,3-triazole (33). - A solution of azide 16 (1.015 g, 5.0 mmol) and methyl propiolate (0.546 g, 6.5 mmol) in dimethoxyethane (10 ml) was heated under reflux for 5 h. The residue after evaporation was chromatographed on silica, with dichloromethane-methanol (99:1) as eluent to give firstly the 5-methoxycarbonyl isomer 32 (0.200 g, 14%), as an oil; δ_H 2.1 (1H, br. s, OH), 3.45 and 3.47 [each 3H, s, CH(OMe)₂], 3.94 (3H, s, CO₂Me), 3.95 (1H, t, J ~6, 2'-H), 4.37 (1H, dd, J 10.0, 7.5, 5'-H), 4.48 (1H, dd, J 10.0, 4.0, 5'-H), 4.53 [1H, d, J 6.5, CH(OMe)₂], 4.87 (1H, dd, J 6.0, 4.5, 3'-H), 5.59 (1H, m, 4'-H), 8.18 (1H, s, 5-H) [Found: (M-MeO)⁺ (EI) 256.09258. Calc. for C₁₀H₁₄N₃O₅ 256.09335].

Further elution of the column gave the 4-methoxycarbonyl triazole 33 (1.128 g, 79%) as an oil, $[\alpha]_D +76.6$ (c 1.4, MeOH); δ_H 3.48 and 3.50 [each 3H, s, CH(OMe)₂], 3.92 (1H, t, J 5.0, 2'-H), 3.94 (3H, s, CO₂Me), 4.27 (1H, dd, J 10.0, 4.0, 5'-H), 4.37 (1H, dd, J 10.0, 5.5, 5'-H), 4.50 [1H, d, J 5.0, CH(OMe)₂], 4.58 (1H, dd, J 5.0, 3.0, 3'-H), 5.15 (1H, m, 4'-H), 8.36 (1H, s, 5-H) (Found: C, 45.8; H, 6.1; N, 14.5. C₁₁H₁₇N₃O₆ requires C, 45.99; H, 5.92; N, 14.63%).

(2'R, 3'R, 4'S)-4-Carboxamido-1-(2'-dimethoxymethyl-3'-hydroxytetrahydrofuran-4'-yl)-1,2,3-triazole (34). - A solution of ester 33 (0.948 g, 3.3 mmol) in saturated methanolic ammonia was maintained at r.t. overnight then lyophilized. The residue was crystallized from ethyl acetate to give amide 34 (0.852 g, 90%) m.p. 152-

154 °C, $[\alpha]_D +70.9$ (c 1.72, MeOH); δ_H (DMSO- d_6) 3.30 (6H, s, OMe), 3.75 (1H, t, J 5.0, 2'-H), 4.18 (2H, d, J 6.0, 5'-H₂), 4.33 [1H, d, J 5.5, CH (OMe)₂], 4.45 (1H, m, 3'-H), 5.00 (1H, q, J ~5, 4'-H), 5.95 (1H, br.s, OH), 7.50 and 7.90 (each 1H, br.s, NH₂), 8.52 (1H, s, 5-H); δ_C (DMSO- d_6) 53.6 and 54.9 (OMe), 68.0 and 69.7 (CH), 77.0 (C-5'), 84.9 (CH), 103.5 [CH (OMe)₂], 125.5 (C-5), 142.8 (C-4) 161.3 (amide); m/z (FAB) 273 (MH⁺), 241 (M-MeO)⁺ [Found: C, 44.4; H, 6.1; N, 20.8. C₁₀H₁₆N₄O₅ requires C, 44.11; H, 5.88; N, 20.58%. Found: (M-OMe)⁺ (EI) 241.08707. Calc. for C₉H₁₃N₄O₄, 241.09368].

(2'S, 3'R, 4'S)-4-Carboxamido-1-(3'-hydroxy-2'-hydroxymethyltetrahydrofuran-4'-yl)-1,2,3-triazole (13). - The amide 34 (0.41 g, 1.5 mmol) was treated and processed as in the preparation of 12 above to give the diol 13 (0.21g, 61%), m.p. 182-184 °C (from ethyl acetate), $[\alpha]_D +73.9$ (c 1.1, MeOH); δ_H (DMSO- d_6) 3.4-3.7 (3H, m, 2'-H, CH₂OH), 4.09 (1H, dd, J 9.9 and 4.4, 5'-H), 4.17 (1H, dd, J 10.0 and 5.5, 5'-H), 4.32 (1H, dd, J 5.7 and 4.2, 3'-H), 4.92 (1H, br.s, OH), 5.05 (1H, dt, J 6.2, 4.2 and 4.2, 4'-H), 5.90 (1H, br.s, OH), 7.48 and 7.89 (each 1H, br.s, NH₂), 8.54 (1H, s, 5-H); δ_C (DMSO- d_6) 61.0 (CH₂OH), 68.4 (CH), 70.4 (C-5'), 77.1 (CH), 86.3 (CH), 125.9 (C-5), 143.5 (C-4), 161.9 (amide) [Found: MH⁺ (FAB) 229.0958. Calc. for C₈H₁₃N₄O₄, 229.0937].

ACKNOWLEDGEMENTS

We thank MRC for financial support, EPSRC for access to facilities at the National Mass Spectrometry Service Centre, University of Wales, Swansea, and Dr Naheed Mahmood (MRC Collaborative Centre, Mill Hill) for the antiviral tests.

REFERENCES AND NOTES

1. Lambert, J.S.; Seiglin, M.; Reichman, R.C.; Plank, C.S.; Dolin, R. *New Engl. J. Med.*, **1990**, *332*, 1333.
2. Mitsuya, H.; Broder, S. *Proc. Natl. Acad. Sci. U.S.A.* **1986**, *83*, 1911.
3. Fischl, M.A.; Richman, D.D.; Grieco, M.H. *New Engl. J. Med.*, **1987**, *317*, 185.
4. Kim, H.O.; Schinazi, R.F.; Shanmuganathan, K.; Jeong, L.S.; Beach, J.W.; Nampalli, S.; Cannon, D.L.; Chu, C.K. *J. Med. Chem.*, **1993**, *36*, 519, and refs. therein.
5. Jeong, L.S.; Schinazi, R.F.; Beach, J.W.; Nampalli, S.; Shanmuganathan, K.; Alves, A.J.; McMillan, A.; Chu, C.K.; Mathis, R. *J. Med. Chem.*, **1993**, *36*, 182, and refs. therein; Belleau, B.; Brasili, L.; Chan, L.; DiMarco, M.P.; Zacharie, B.; Nguyen-Ba, N.; Jenkinson, H.J.; Coates, J.A.V.; Cameron, J.M. *Bioorg. Med. Chem. Lett.*, **1993**, *3*, 1723.
6. Huryn, D.M.; Sluboski, B.C.; Tam, S.Y.; Todaro, L.J.; Weigle, M. *Tetrahedron Lett.*, **1989**, *30*, 6259; Huryn, D.M.; Sluboski, B.C.; Tam, S.Y.; Weigle, M.; Sim, I.; Anderson, B.D.; Mitsuya, H.; Broder, S. *J. Med. Chem.*, **1992**, *35*, 2347.
7. Jones, M.F.; Noble, S.A.; Robertson, C.A.; Storer, R.; Highcock, R.M.; Lamont, R.B. *J. Chem. Soc., Perkin Trans. I*, **1992**, 1437.
8. Bolon, P.J.; Sells, T.B.; Nuesca, Z.M.; Purdy, D.F.; Nair, V. *Tetrahedron*, **1994**, *50*, 7747; Nair, V.; St. Clair, M.H.; Reardon, J.E.; Krasny, H.C.; Hazen, R.J.; Paff, M.T.; Boone, L.R.; Tisdale, M.; Najera, I.; Dornsife, R.E.; Averett, D.R.; Borrotoesoda, K.; Yale, J.L.; Zimmerman, T.P.; Rideout, J.L. *Antimicrobial Agents Chemother.*, **1995**, *39*, 1993.
9. Kakefuda, A.; Shuto, S.; Nagahata, T.; Seki, J.; Sasaki, T.; Matsuda, A. *Tetrahedron*, **1994**, *50*, 10167.

10. Marquez, V.E.; Tseng, C.K.-H.; Kelley, J.A.; Mitsuya, H.; Broder, S.; Roth, J.S.; Driscoll, J.S. *Biochem. Pharmacol.*, **1987**, *36*, 2719.
11. (a) Siddiqi, S.M.; Chen X.; Schneller, S.W. *Bioorg. Med. Chem. Lett.*, **1992**, *2*, 1279; (b) Schneller, S.W.; Chen, X.; Siddiqi, S.M. Carbocyclic 7-Deazaguanosine Nucleosides as Antiviral Agents. In *Nucleosides and Nucleotides as Antitumour and Antiviral Agents*; Chu, C.K.; Baker D.C. Eds.; Plenum Press: New York, 1993; pp 141-158; (c) Legraverend, M.; Ngono-Tekam, R.-M.N.; Bisagni, E.; Zerial, A. *J. Med. Chem.*, **1985**, *28*, 1477; (d) Saxena, N.K.; Hagenow, B.M.; Genzlinger, G.; Turk, S.R.; Drach, J.C.; L.B. Townsend, L.B.; *J. Med. Chem.*, **1988**, *31*, 1501; (e) Seela, F.; Muth, H.-P.; Röling, A. *Helv. Chim. Acta*, **1991**, *74*, 554.
12. Franchetti, P.; Cappellacci, L.; Grifantini, M.; Messini, L.; Abu Sheikha, G.; Loi, A.G.; Tramontano, E.; De Montis, A.; Spiga, M.G.; La Colla, P. *J. Med. Chem.*, **1994**, *37*, 3534.
13. For recent overviews of this area see: Sanghvi, Y.S.; Cook, P.D. Eds. *ACS Symp. Ser.*, **1994**, *580* (Carbohydrate Modifications in Antisense Research); De Mesmaeker, A.; Altmann, K.-H.; Waldner, A.; Wendeborn, S. *Curr. Opin. Struct. Biol.*, **1995**, *5*, 343.
14. Tam, S.; Holman, M.; Huryn, D.; Cislo, A. *Nucleosides Nucleotides*, **1991**, *10*, 245.
15. Moravková, J.; Capková, J.; Stanek, J. *Carbohydr. Res.*, **1994**, *263*, 61.
16. Defaye, J.; Horton, D.; Muesser, M. *Carbohydr. Res.*, **1971**, *20*, 305.
17. Cristalli, G.; Franchetti, P.; Grifantini, M.; Vittori, S.; Lupidi, G.; Riva, F.; Bordoni, T.; Geroni, C.; Verini, M.A. *J. Med. Chem.*, **1988**, *31*, 390; Montgomery, J.A.; Hewson, K. *J. Med. Chem.*, **1967**, *10*, 665.
18. Huryn, D.M.; Tam, S.Y.K.; Weigle, M. **1989**, European Patent Appl. EP 383,239 (U.S. Appl. 309561); *Chem. Abstr.*, **1990**, *114*, P 229303.
19. Witkowski, J.T.; Robins, R.K.; Sidwell, R.W.; Simon, L.N. *J. Med. Chem.*, **1972**, *15*, 1150; Smith, R.A.; Sidwell, R.W.; Robins, R.K. *Ann. Rev. Pharm. Tox.*, **1980**, *20*, 259.

(Received in UK 31 December 1996; accepted 23 January 1997)